JP2018503610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503610A5 JP2018503610A5 JP2017532648A JP2017532648A JP2018503610A5 JP 2018503610 A5 JP2018503610 A5 JP 2018503610A5 JP 2017532648 A JP2017532648 A JP 2017532648A JP 2017532648 A JP2017532648 A JP 2017532648A JP 2018503610 A5 JP2018503610 A5 JP 2018503610A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- lymphoma
- administered
- cell
- ibrutinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 12
- 229960001507 ibrutinib Drugs 0.000 claims 12
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 230000036210 malignancy Effects 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 206010066476 Haematological malignancy Diseases 0.000 claims 8
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 5
- 229960003347 obinutuzumab Drugs 0.000 claims 4
- 229960002450 ofatumumab Drugs 0.000 claims 4
- 229960005267 tositumomab Drugs 0.000 claims 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 229940126611 FBTA05 Drugs 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 239000011630 iodine Substances 0.000 claims 2
- 229960002358 iodine Drugs 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 229950005751 ocrelizumab Drugs 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 201000004085 CLL/SLL Diseases 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical group OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 208000021173 high grade B-cell lymphoma Diseases 0.000 claims 1
- 229960003445 idelalisib Drugs 0.000 claims 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096284P | 2014-12-23 | 2014-12-23 | |
| US62/096,284 | 2014-12-23 | ||
| PCT/US2015/067504 WO2016106381A1 (en) | 2014-12-23 | 2015-12-22 | Btk inhibitor combinations and dosing regimen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018503610A JP2018503610A (ja) | 2018-02-08 |
| JP2018503610A5 true JP2018503610A5 (enExample) | 2019-02-07 |
Family
ID=56151542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532648A Pending JP2018503610A (ja) | 2014-12-23 | 2015-12-22 | Ｂｔｋ阻害剤の組み合わせ及び投与レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170360796A1 (enExample) |
| EP (1) | EP3236968A4 (enExample) |
| JP (1) | JP2018503610A (enExample) |
| CN (1) | CN107106565A (enExample) |
| AU (1) | AU2015369665A1 (enExample) |
| BR (1) | BR112017013580A2 (enExample) |
| CA (1) | CA2970043A1 (enExample) |
| HK (1) | HK1245153A1 (enExample) |
| MX (1) | MX2017008486A (enExample) |
| WO (1) | WO2016106381A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ717373A (en) | 2010-06-03 | 2017-11-24 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
| WO2018033941A2 (en) * | 2016-08-19 | 2018-02-22 | Cipla Limited | Pharmaceutical compositions of ibrutinib |
| TW201922256A (zh) * | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
| WO2019127008A1 (zh) * | 2017-12-26 | 2019-07-04 | 清华大学 | 一种靶向降解btk的化合物及其应用 |
| CA3098497A1 (en) | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| CA3151560A1 (en) * | 2019-10-04 | 2021-04-08 | Takaaki FUJIMURA | Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2024183817A1 (zh) * | 2023-03-09 | 2024-09-12 | 浙江特瑞思药业股份有限公司 | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| JP5960688B2 (ja) * | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| NZ717373A (en) * | 2010-06-03 | 2017-11-24 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| US20140303191A1 (en) * | 2011-10-19 | 2014-10-09 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| GB201207305D0 (en) * | 2012-04-26 | 2012-06-13 | E Therapeutics Plc | Therapy |
| JP2016512549A (ja) * | 2013-03-14 | 2016-04-28 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ |
| EP3004106B1 (en) * | 2013-06-07 | 2017-08-30 | Rhizen Pharmaceuticals S.A. | Dual selective pi3 delta and gamma kinase inhibitors |
| US20170231995A1 (en) * | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment |
-
2015
- 2015-12-22 WO PCT/US2015/067504 patent/WO2016106381A1/en not_active Ceased
- 2015-12-22 JP JP2017532648A patent/JP2018503610A/ja active Pending
- 2015-12-22 MX MX2017008486A patent/MX2017008486A/es unknown
- 2015-12-22 AU AU2015369665A patent/AU2015369665A1/en not_active Abandoned
- 2015-12-22 CN CN201580073032.7A patent/CN107106565A/zh active Pending
- 2015-12-22 BR BR112017013580A patent/BR112017013580A2/pt not_active Application Discontinuation
- 2015-12-22 EP EP15874346.8A patent/EP3236968A4/en not_active Withdrawn
- 2015-12-22 HK HK18104957.3A patent/HK1245153A1/zh unknown
- 2015-12-22 CA CA2970043A patent/CA2970043A1/en not_active Abandoned
- 2015-12-22 US US15/538,276 patent/US20170360796A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503610A5 (enExample) | ||
| CN115279376A (zh) | 用于治疗异常细胞生长的组合疗法 | |
| JP2019536805A5 (enExample) | ||
| ES2945387T3 (es) | Procedimientos y composiciones para tratar el crecimiento celular anormal | |
| JP2025072587A (ja) | 治療組成物、組み合わせ、及び使用方法 | |
| JP2020514311A5 (enExample) | ||
| JP2011503063A5 (enExample) | ||
| JP2004512262A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2020505433A5 (enExample) | ||
| JP2015212268A5 (enExample) | ||
| CN116056699A (zh) | 用于治疗异常细胞生长的组合疗法 | |
| HRP20171727T1 (hr) | Novi terapeutici | |
| JP2016515628A5 (enExample) | ||
| KR20180043356A (ko) | 담관암의 치료법 | |
| JP2019508476A5 (enExample) | ||
| JP2019526595A5 (enExample) | ||
| JP2020516646A5 (enExample) | ||
| JP2019517485A5 (enExample) | ||
| JP2012510484A5 (enExample) | ||
| JP2015172060A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| Lee et al. | S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer: results from the randomized phase III POST trial | |
| JP2018506533A5 (enExample) |